CrossMark

Psychological Aspects of Cardiac Care and Rehabilitation: Time to Wake Up to Sleep?

Jonathan Gallagher[1] · Giulia Parenti[2] · Frank Doyle[3]

Abstract Psychological and psychosocial factors have long been linked to cardiovascular disease. These psychosocial factors, including low socioeconomic status, social support/isolation, stress and distress, personality, and sleep disturbance increase risk of cardiovascular events and negatively impact quality of life. These factors may have direct effects on cardiovascular disease via immune or neuroendocrine pathways, or more indirect effects, by, for example, limiting adherence to recommended therapies and cardiac rehabilitation. Most psychosocial risk factors can be assessed relatively easily using standardised tools. Sleep disturbance, in particular, is gaining evidence for its importance and may be crucial to address. While the management of certain psychosocial risk factors is an ethical requirement for care and improves quality of life, unfortunately there is little evidence that such strategies impact on 'hard' endpoints such as recurrent myocardial infarction. A comprehensive biopsychosocial approach to management of these psychosocial factors is required to maximise the benefits patients derive from cardiac care.

Keywords Psychosocial risk factors (PSRFs) · Cardiovascular disease · Depression/anxiety · Psychological management · Cardiac rehabilitation · Sleep

✉ Jonathan Gallagher
jonathangallagher@beaumont.ie

Giulia Parenti
giulia.parenti@studenti.unipd.it

Frank Doyle
FDoyle4@rcsi.ie

1   Department of Cardiology (Cardiac Rehabilitation), Beaumont Hospital, Beaumont, Dublin 9, Ireland

2   Department of General Psychology, University of Padua, Padua, Italy

3   Department of Psychology, Royal College of Surgeons in Ireland, Lower Mercer Street, Dublin 2, Ireland

Introduction

A growing evidence base suggests that a range of psychosocial risk factors (PSRFs) are linked to the pathogenesis of cardiovascular disease (CVD). Factors such as anxiety, depression, and low socioeconomic status have been reliably linked with both the development of cardiovascular disease and poorer prognosis post-onset [1, 2••]. In addition, the ubiquitous term 'stress' is now an established feature of modern parlance and may be an increasingly important determinant of cardiovascular health. In the face of improvement in traditional risk factors for CVD, PSRFs such as chronic stress show no sign of abating. For example, the INTERHEART study of 11,119 patients with myocardial infarction (MI) from 52 countries demonstrated that perceived stress and depression accounted for 32.5 % of the population attributable risk for CVD, suggesting that when combined, they were as important as smoking and more important than hypertension (17.9 %) and diabetes (9.9 %) [3]. Furthermore, greater than 90 % of the causes of CVD identified by this landmark study were attributable to modifiable risk factors, largely influenced by health behaviours, which are in turn impacted by PSRFs. In fact, PSRFs play such a prominent role in a multifactorial condition such as CVD that they have been incorporated into the guidelines of medical associations [2••], in order to maximise the effectiveness of treatment of this population and deliver truly biopsychosocial care.

🖄 Springer

The aims of the current review are to (a) summarise the extant literature regarding the links between PSRFs and cardiovascular disease; (b) provide an overview of the management of psychological aspects of CVD, with a particular focus on cardiac rehabilitation, and make recommendations as appropriate; and (c) highlight emerging areas of interest and identify potentially novel targets for cardiovascular disease reduction (e.g. insomnia). Although this paper will primarily refer to psychological aspects of care targeted in the setting of cardiac rehabilitation, the experiences of patients with heart failure or those living with an ICD will also be addressed to some extent. Functional heart complaints (e.g. non-cardiac chest pain) are beyond the scope of the current review, but with regard to emerging areas of interest, particular attention will be given to the role of sleep disturbance.

PSRFs and CVD Outcomes

Social Factors and CVD

Low Socioeconomic Status

Various systematic reviews have documented an association between low socioeconomic status (SES) (defined as low education level, low income, holding a manual job, or residing in a disadvantaged area) and an increased risk of cardiac and all-cause mortality risk [4–6]. Patients recovering from an MI with both low income and low educational attainment have a significantly increased risk of mortality [7]. Furthermore, patients of low SES with CHD are less adherent to secondary preventive medications [8], have poorer behavioural control of cardiac risk factors [9], and may even benefit less from cardiac rehabilitation (CR) [10]. Unfortunately, there is also consistent evidence that those of lower SES are less likely to attend/complete CR [11••, 12]. While CR programmes primarily attempt to mitigate the SES-CVD link by addressing the cardiac risk factors known to account for much of this relationship [13], selected interventions have been shown to increase the uptake of CR programmes in patients of low SES [14], although the evidence to support interventions that improve adherence is weak [15]. Financial incentives have also been explored for their potential to improve CR participation rates in patients from disadvantaged communities [16]. However, while these interventions are promising [17], further studies are needed to determine costs and generalisability of findings. Although it is important to identify and target patients with low SES, efforts should also be taken by CR staff to accommodate patients with associated literacy difficulties by avoiding the use of medical jargon and communicating with patients using a language that is familiar to them.

Social Isolation and Poor Social Support

Social isolation refers to the circumstances in which one lives (i.e. alone or with others) whereas social support relates to the availability of practical or emotional support enjoyed by an individual. The evidence that social isolation and low social support respectively increase the risk of incident CVD in healthy people is much less convincing than prognostic studies of their effect in patients with established CVD and/or MI [18, 19]. A recent meta-analysis established that a smaller social network was less important than low functional support (e.g. tangible and perceived emotional support) in predicting increased cardiac and all-cause mortality, even after controlling for other somatic factors [19]. While it was initially thought that high levels of social support may moderate the effect of depression on mortality in post-MI patients [20], the Enhancing Recovery in Coronary Heart Disease (ENRICHD) trial, which targeted and improved perceived social support, had no impact on cardiac endpoints [21]. Although there is currently insufficient data to inform clear recommendations regarding targeting social support in patients with CHD, attempts to enhance social support and reduce social isolation should definitely be encouraged; however, these efforts are more likely to improve quality of life than cardiac outcomes.[22]. Social support may be addressed both directly and indirectly in CR, via individual psychological support, a therapeutic group dynamic, family interventions (e.g. spousal anxiety/ caregiver burden), onward referral to specialised community supports (e.g. ICD support groups), and the enlisting peer support to facilitate adherence to lifestyle changes post-CR (e.g. phase IV exercise maintenance programmes) [2••, 23]. With regard to identifying at-risk patients, the ENRICHD Social Support Instrument (ESSI) is recommended as a screening measure for low perceived social support in CR and has been shown to be predictive of cardiac endpoints [2••, 24].

Personality Characteristics and CVD

Type A Behaviour Pattern

Type A behaviour pattern (TABP) refers to a combination of highly competitive goal-oriented behaviour, impatience, time urgency, cynical hostility, and frequent expressions of anger. This behavioural pattern was the first psychosocial risk factor in CHD to be studied scientifically [25] and was considered the most likely candidate for a 'coronary prone personality' until the late 1980s, when anger and hostility were identified as the "toxic" components of TABP [26]. Subsequent research has since focused on these two constructs to the detriment of TABP, and a meta-analysis concluded that 'type A personality' was not a valid indicator of cardiac prognosis [26]. Some observers have suggested that TABP may have suffered a

premature demise given recent evidence showing that interventions targeting TABP have led to improved depression [27••] and even improved cardiac endpoints for female CHD patients in particular [28, 29]. Aspects of TABP are also implicitly addressed in interventions such as transcendental meditation (TM) and mindfulness-based stress reduction (MBSR) which are sometimes available to patients attending CR [30].

Anger and Hostility

Anger is a transient emotional state associated with feeling threatened or frustrated, whereas *hostility* is more of a persistent attitude of opposition and anger towards others [31]. Hostile beliefs and attitudes (e.g. cynicism and mistrust of others' motives) are considered to lower the anger provocation threshold, and anger-proneness as a trait is the tendency to experience more frequent, pronounced, and prolonged episodes of anger and resentment [31]. In a recent meta-analysis, the presence of anger and hostility were shown to both precede the development of CHD and worsen its course [32]. Few studies have investigated the effects of anger-specific interventions on recurrent cardiac events or survival. In comprehensive CR, treatments typically address anger/hostility only as one component of stress management and address, for example, the popular misconception that "holding anger in" is hazardous to one's health and should therefore be expressed regularly [33], an assumption not supported by empirical findings on the cardiovascular effects of anger [34]. Cognitive behavioural stress management (CBSM) has been shown to significantly reduce anger/hostility in ICD recipients, but not arrhythmias or other cardiovascular outcomes [35], and exercise-based CR has also been shown to reduce anger and hostility in patients with CHD [36]. Although a reduction in hostility may contribute to reduced mortality risk in patients with CHD [37], this finding needs to be replicated in more rigorously designed studies. While identifying clinically significant anger/hostility is recommended in patients attending CR [2••], targeting anger in isolation is unlikely to be as impactful as taking a more comprehensive approach as may be achieved in the setting of CR. Expanded psychosocial interventions that encompass anger management in addition to other modes of treatment (e.g. exercise, pharmacotherapy) may be more likely to improve cardiovascular outcomes in these patients [38].

Type D Personality

The emergence of type D or 'distressed' personality [39] brought renewed interest in the role of personality traits as vulnerability factors for adverse health outcomes in cardiac patients, but recent literature in this area has been critical. Similar to hostility, type D individuals are characterised by a general propensity to psychological distress (negative affectivity), but unlike their hostile counterparts, they have a tendency to consciously inhibit self-expression in social interactions to avoid disapproval of others (social inhibition) [39]. These traits are thought to operate synergistically [39], and type D cardiac patients have been found to be less adherent to cardioprotective medications, to view their heart condition more negatively, to experience higher levels of depressive symptoms over time, and to gain fewer benefits from CR [40–44]. While a number of meta-analyses have also shown type D personality to predict worsened prognosis in persons with CHD [45, 46], recent studies have failed to replicate these results [47–50], which has generated considerable critique. Critics of type D highlight that the majority of these studies included small samples were conducted by a single investigator group and statistically analysed type D personality as a dichotomized variable instead of an interaction term, thereby increasing the risk of spurious results [50–52]. Although type D patients have been shown to improve in health status following CR, they do not experience the same health gains as non-type D patients [53], and firm empirical evidence that interventions targeting this population result in improved outcomes is lacking. Potential interventional strategies in the context of type D personality have been identified to focus on mood (e.g. cognitive behavioural therapy (CBT), relaxation training, mindfulness-based stress reduction), health behaviours (e.g. smoking cessation, exercise therapy), and interpersonal functioning (e.g. interpersonal therapy (IPT), assertiveness training) [54]. Irrespective of the controversy surrounding type D, there is a clinical rationale to formally screen for distressed cardiac patients who, by definition, are likely to conceal their suffering and who may be at risk for non-adherence to recommended therapies such as CR.

Stress and CVD

Work Stress

The majority of studies examining the link between stress and cardiovascular disease have focused on situational stressors, with chronic work stress being the most widely investigated. Individuals who report excessive work demands coupled with low decisional latitude are deemed to be experiencing "job strain" [55]. However, a recent meta-analysis found only a small increase in incident CHD associated with job strain (HR 1·23; 95 % CI 1·10–1·37) [56]. Similarly, the perception of an imbalance between the effort of work (e.g. demands, challenges, sacrifices) and its associated rewards (e.g. financial, self-esteem, advancement opportunities) is understood as the effort-reward imbalance (ERI) model of work stress [57] and has also been investigated with respect to its ability to predict CHD. A meta-analysis examining this relationship did not find a significant effect [58]. There is a distinct lack of intervention studies evaluating the effect of reducing work stressors on CHD risk, although there is some evidence that

the effects of job strain can be mitigated by attending CR [59]. Return to work is an explicit goal of CR, and vocational counselling is a feature of many CR programmes [60]. Psychological interventions specifically targeting work stress primarily comprise of tailored individual stress management and may focus on (a) increasing social support at work, (b) reduction of job demands (e.g. avoiding overtime, assertiveness training, pacing, delegating, modifying work practices), and (c) targeting 'overcommitment' to work (e.g. re-establishing work-life balance, challenging perfectionistic thinking) [61].

Acute Stressors and Stressful Life Events

Acute mental stressors may serve as 'triggers' to cardiac events including acute coronary syndrome (ACS) [62], Takotsubo ('stress-induced') cardiomyopathy [63] or ventricular arrhythmias [64], with these events particularly seen in patients with established CHD. Intense episodes of anger have been shown to trigger cardiac events within 2 h [65•], and other acute stressors such as natural disasters, major sporting events, bereavements, and military/terrorist attacks have been shown to transiently increase cardiac events, e.g.[66, 67]. Although stress management interventions with cardiac patients have successfully targeted potential triggers such as anger [28], overall, there is currently no strong evidence for specific modes of prevention for acute stressors in individuals. In light of this, efforts to buffer the cardiovascular impact of acute stressors via health behaviours (e.g. exercise, diet) should also be encouraged. Equally, while cardiac patients should be helped to acquire stress management skills in CR, it is also important to convey to patients that successfully coping with a hectic lifestyle is not harmful to their cardiac health, and staff should be vigilant to signs of excessively cautious behaviour borne of such misconceptions which may inadvertently impede patients' physical and/or psychological recovery (e.g. avoidance of exercise, excitement, sexual activity) [68].

Stress Management in Cardiac Care

Stress management interventions in CR typically target chronic stress, and it has been suggested that they provide an incremental impact to exercise-based CR [69]. However, while a recent Cochrane review of psychological interventions for patients with CHD demonstrated small to moderate improvements in depression and anxiety with such interventions, there was no strong evidence that they reduced cardiac morbidity or mortality [70]. Similarly, although encouraging results have been reported for interventions such as mindfulness-based stress reduction, TM, and yoga, overall, these studies have been of low quality and thus no firm recommendations can be made for their ancillary use with cardiac populations [30, 71]. Stress management programmes most likely to be effective with cardiac

populations should be multimodal and intensive, initiated only after the acute phase of illness has passed, delivered by appropriately trained clinicians and possibly should involve booster sessions after the intervention has been completed [28, 72, 73].

Emotional Distress and CVD

Depression

Approximately 20 % of patients with CHD meet Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria for major depression, with up to a further 31 % evidencing subclinical levels of depressive symptoms [74•, 75••]. Rates of depression in women with CHD are double than those of men, and it is possible that depressive symptoms may have a different aetiology between sexes [74•]. While mild depression may remit spontaneously for some, depressive symptoms typically persist in about half of the affected patients [40, 76, 77] and can negatively affect the course of their recovery [77]. In patients living with an ICD, major depression ranges from 11 to 28 % [78] and has been shown to predict both the incidence of shock therapy and mortality [79, 80]. The prevalence of depression in patients with chronic heart failure is even greater and tends to increase with the clinical severity of heart failure [81]. Both major depression and elevated depressive symptoms have been associated with both an increased risk of developing CVD and an increased risk of death in patients with existing CVD in several meta-analyses [74•, 75••, 81, 82]. Accordingly, a recent AHA scientific statement recommended that depression should be elevated to the status of independent risk factor for poor prognosis in patients with ACS [83•].

Patients with CHD and co-morbid depression are more likely to experience physical limitations and poorer quality of life, often independent of objective measures of cardiac function [2••]. Depression is also associated with other behavioural risk factors for heart disease, such as smoking and medication non-adherence [2••, 84–86] and reduced participation in cardiac rehabilitation [87, 88]. Although studies suggesting links between particular subtypes of depression (e.g. somatic or anhedonic depression) have tended to be inconsistent [89, 90], recent meta-analytic findings suggest that somatic/affective (e.g. insomnia, fatigue) rather than cognitive/affective (e.g. guilt, pessimism) symptoms of depression may predict increased risk of mortality seen in CHD patients [91•]. Such somatic symptoms are suspected to be a physiological consequence of CVD processes, and some authors hypothesise that depression should be seen as a variable risk marker, rather than risk factor, for CVD [92].

Although a number of psychotherapeutic and pharmacological options exist to treat depression, treatments that improve both depression and reduce the risk of cardiovascular events have not yet been identified. For example, CBT, IPT, and problem-solving therapy (PST) have all

been shown to be beneficial for depression in cardiac patients but did not affect cardiac endpoints [21, 93, 94••]. Currently, collaborative care, or stepped care, is considered to be optimal in treating cardiac patients with a depressed mood [95, 96••]. The COPES trial employed a stepped-care treatment approach in patients with ACS and persistent depression, involving an initial patient choice of PST and/or pharmacotherapy [94••]. This intervention resulted in significantly less depression after 6 months compared to usual care, and although most patients chose to commence PST initially, half were treated with medication by the end of the trial due to persistent depression. Exercise has also been evaluated as a treatment for depression, with the UP-BEAT trial demonstrating that for patients with CHD and concurrent depressed mood, 4 months of aerobic exercise training three times weekly was as effective as antidepressant medication for improving a depressed mood [97••]. Similarly, the HF-ACTION randomised trial of 2322 patients with heart failure (28 % of whom were depressed) demonstrated that exercise not only reduced mortality and hospitalisation but also significantly reduced depression with this effect remaining after 1 year [98••].

Although antidepressant medications (typically SSRIs) have been shown to improve depression in patients with CHD, particularly in patients with relapsing or severe depression [21], a stable finding across trials appears to be that there is little, if any, evidence that pharmacotherapy improves cardiac endpoints in depressed patients with CHD [21, 99], and in patients with heart failure, antidepressant medication has not been demonstrated to increase survival *or* significantly reduce depression [100].

Cardiac patients may be reticent to disclose a depressed mood [101], and depression in patients with heart failure frequently goes unnoticed as symptoms such as tiredness, sleep disturbance, and impaired concentration are typical of the cardiac disease itself. However, a large proportion of CR programmes do not routinely screen for depression [102], and screening itself does not necessarily translate into improved clinical outcomes for cardiac patients unless followed by comprehensive care [95, 102]. It is recommended that clinically significant levels of depression be systematically identified via clinical interview and/or use of a brief, reliable screening measure validated in cardiac populations (e.g. PHQ-9) [103]. Screening should ideally take place before hospital discharge, at CR programme entry (i.e. within 2–3 months), and again at CR completion. Staff should be aware of the appropriate referral process, and patients screening positive for depressed mood should be followed up for diagnostic evaluation by a mental health professional. Although the effect on cardiac endpoints is as yet unproven, quality of life is improved with depression treatment, and collaborative care with stepped interventions may result in optimal patient outcomes [104].

Anxiety

Anxiety is a normative response to a potentially life-threatening event, with up to half of hospitalised cardiac patients reporting clinically significant anxiety while in hospital, and this persists in up to 40 % of patients after 1 year [105, 106]. Similarly, the rates of patients meeting criteria for an anxiety disorder reach 18 % in patients with heart failure [107] and 26 % in ICD patients [78], respectively, with nearly half of the latter population exhibiting significant shock anxiety [108]. Furthermore, in a meta-analysis of 24 studies, Edmondson et al. [109] found a 12 % prevalence of PTSD among patients with acute ACS, and there is growing evidence that symptoms of post-traumatic stress both worsen the cardiovascular prognosis of patients with CHD [110] and predict all-cause mortality in patients living with an ICD [111].

Although anxiety is more prevalent than and highly co-morbid with depression [112–114], relatively less is known about anxiety in cardiac patients, although the existing evidence suggests that anxiety disorders per se are less common in this population than sub-clinical levels of anxiety. Anxiety has not been as robust a predictor of cardiac endpoints as depression, and the associations between anxiety and CHD have generally been smaller than those found for depression. Roest et al. [115] found that initially healthy participants with elevated anxiety were at increased risk of CHD (HR 1.26; 95 % CI: 1.15–1.38) as well as cardiac mortality, and this effect was independent of demographic variables and biological and behavioural risk factors. Notably however, the meta-analytic estimate for the association with CHD was not adjusted for depression. A further meta-analysis examining the prognostic association of anxiety in post-MI patients found that elevated anxiety was predictive of all-cause mortality, cardiac mortality, and new cardiac events at 3 years of follow-up [116]. More recently, a study of 1411 patients with CHD found that while both depression and anxiety predicted all-cause mortality 10 years post-PCI, anxiety conferred no additional risk in the case of co-morbid depression [117]. That the effect sizes for anxiety are lower than those for depression raises the possibility that for some cardiac patients, elevated anxiety may in fact be a stimulus for improving health behaviours. While depression has been consistently associated with non-adherence to recommended health behaviours, the evidence is mixed for anxiety [2••, 118], and higher anxiety levels have even been associated with a reduction in both mortality and cardiac events 5 years after coronary stenting [119].

Few randomised controlled trials (RCTs) have explicitly targeted anxiety in cardiac patients. The recent Management of Sadness and Anxiety in Cardiology (MOSAIC) trial examined the impact of a 6-month low-intensity collaborative care intervention compared to usual care, in a population of patients hospitalised for acute cardiac illness (e.g. ACS, heart failure, or arrhythmia) [120]. Cardiac inpatients diagnosed

with major depression, generalised anxiety disorder, or panic disorder were blindly allocated to either 6 months of collaborative management [a low-intensity telephone-based multicomponent intervention targeting depression and anxiety disorders ($n=92$)] or to 'enhanced usual care' ($n=91$), which involved identification of mood/anxiety disorder, serial communication of diagnosis to primary medical providers over 6 months, and provision of emergency care. Interventions were provided by care managers in collaboration with psychiatrists and comprised of psychotherapy and pharmacotherapy on a stepped-care basis. Those patients receiving the intervention experienced greater quality of life at 6 months, greater improvements in depressive symptoms and general functioning, and higher rates of treatment of a mental health disorder. However, anxiety scores, disorder response rates, and adherence did not differ between groups [120].

Comprehensive CR provides a major therapeutic impetus for patients with CHD and has been shown to result in significant improvements in anxiety, particularly in those highly anxious at baseline [27••, 36]. High levels of anxiety in cardiac patients are often driven by maladaptive beliefs about their heart condition [68], and these misconceptions are frequently targeted during CR, in addition to provision of stress management and relaxation training. As with depression, anxiety levels should be assessed before and after CR with a validated screening tool [121], with specialist psychological support considered as appropriate. Although anxiety disorders may substantially contribute to cardiovascular risk, there is currently no convincing evidence that treating them with psychotherapy and/or pharmacotherapy mitigates this risk, in addition to reducing distress. More RCTs are needed to determine if adjustments to the collaborative care model cited above result in greater improvements in mental health.

Health-Related Quality of Life

While quality of life is typically considered an outcome in research studies and practice, more recent research has highlighted how quality of life and health status could be seen as risk factors for prognosis in CVD [2••]. The improvement of health-related quality of life (HRQoL) in cardiac patients is considered an important objective of cardiac rehabilitation and has been increasingly emphasised in cardiac care generally, given that some treatments do not do improve prognosis or are associated with significant psychosocial burden. Studies have also shown that impaired quality of life is predictive of poorer cardiovascular outcomes in patients with CHD and/or heart failure [122–124] although it remains somewhat unclear to what extent this relationship is influenced by disease severity or co-morbid affective disorders, which themselves are known to result in poorer cardiovascular outcomes and HRQoL [125]. Although poorer quality of life is associated

with less uptake of cardiac rehabilitation [126], patients with CHD or heart failure who do attend experience clear improvements [127]. Lifestyle changes targeted by CR (smoking cessation, increased physical activity, cardioprotective diet) when adopted by cardiac patients are also linked with better HRQoL [128]. Changes in illness beliefs during CR have also resulted in enhanced HRQoL in this population. Patients who came to view their heart condition as more understandable perceived fewer emotional consequences and attributed less symptoms to their illness and experienced a better HRQoL upon completing CR [129].

While there are diverse conditions within the spectrum of CVD, often patients receive similar treatments. Therefore, comparison of HRQoL among subgroups has become an important focus. Two HRQoL questionnaires have recently been shown to allow for comparison among different diagnostic groups—the HeartQol and the MacNew [130–132]. The HeartQol, in particular, has demonstrated validity across 22 countries and several languages and has been shown to predict 5-year mortality and cardiac readmissions in patients with ischaemic heart disease [133]. Aside from evaluating the effectiveness of CR, this measure may also aid in identifying patients at higher risk for CVD events and thus inform treatment planning [134].

Sleep and CVD

Sleep was not considered as a risk factor for CVD until relatively recently. The INTERHEART study, for example, conflated sleep with stress by not measuring it directly but rather including it in their measure of stress [3]. However, research over the last decade or so has provided convincing evidence that sleep disturbances independently contribute to poorer cardiovascular health [135, 136] and may represent important novel targets for CVD reduction. Studies examining the association of impaired sleep with cardiovascular health have focused on shiftwork (intermittently misaligned sleep), short and long sleepers, obstructive sleep apnoea (OSA), and more recently, insomnia [137]. A recent systematic review and meta-analysis showed shiftwork to be associated with 23–24 % increase in risk for MI and CVD events but not for mortality. All shiftwork schedules other than evening shifts increased the risk of cardiac events, even after adjusting for behavioural and biomedical risk factors [138]. Meta-analyses have also identified sleep of either long (≥ 8 to 9 h) or short (≤ 5 to 6 h) duration as risk factors for CVD [139]. While it has been posited that longer duration of sleep may be simply a marker of depression or medical co-morbidities [140], the causes of short sleep duration are more varied (e.g. insomnia, shiftwork) and often behavioural (e.g. poor sleep hygiene, type A behaviour). Short sleep duration has been associated with an increased risk of hypertension in particular [141, 142], in addition to

neuroendocrine and autonomic dysfunction, inflammation, and appetitive factors [143]. Conversely, in a large prospective study of 17,887 adults aged 20–65 years and free of CVD at baseline, the addition of sufficient sleep (≥7 h) to four cardioprotective lifestyle factors (sufficient physical activity, healthy diet, moderate alcohol intake, and non-smoking) resulted in a 65 % lower risk of composite CVD (HR 0·35; 95 % CI 0·23–0·52) and an 83 % lower risk of fatal CVD (HR 0·17; 95 % CI 0·07–0·43) [144].

OSA is characterised by a partial or complete blockage of the upper airway, typically caused by the soft tissue at the back of the throat collapsing during sleep due to lack of muscle tone. Increased sympathetic activity, surges in blood pressure, and other mechanisms such as oxidative stress, systemic inflammation, metabolic abnormalities, and endothelial dysfunction are thought to contribute to the development of atherosclerosis [145], and OSA has been associated with a 70 % relative increased risk of cardiovascular morbidity and mortality [146]. OSA is highly prevalent (~66 %) but underdiagnosed in cardiac patients [147, 148], and findings suggest that OSA results in decreased cardiac function in patients attending CR, thereby impeding recovery from their cardiac event [148]. Treating OSA in both cardiac and hypertensive patients may result in reduced cardiovascular morbidity and mortality [149, 150] and consequently the importance of routine OSA screening in CR populations has been stressed [147, 151].

Insomnia and OSA are highly co-morbid and operate synergistically to result in poorer outcomes in both hypertensive and depressed patients [152]. Similarly, although insomnia and short sleep duration are clearly related, they represent different entities, in that insomnia necessitates dissatisfaction with the quality of sleep and the accompanying daytime consequences which may or may not be explained by objectively reduced sleep duration. A recent meta-analysis of 13 prospective studies identified insomnia as a risk factor (RR 1.45, 95 % CI 1.29–1.62) for developing or dying from cardiovascular disease [153], and insomnia has also been associated with several adverse cardiometabolic risk factors [154], especially when accompanied by short sleep duration [155]. Chronic insomnia with *objectively measured* short sleep duration is considered to be the most severe biological phenotype of the disorder, particularly with regard to cardiovascular mortality [156], and both hypertension and biomarkers of systemic inflammation (e.g. C-reactive protein) have been posited to account for this observed increase in mortality [154, 156, 157].

Importantly, the emergence of DSM-5 insomnia disorder (ID) confirmed that insomnia in cardiac patients may no longer be assumed to be merely an associated symptom of depression and anxiety and likely to co-remit. Rather, studies have shown that sleep disturbance typically continues following a depressive episode [158], and residual insomnia symptoms following treatment for depression increase the risk of depressive relapse [159]. Insomnia is highly prevalent in

cardiac patients (~37 %) [160], and poor sleep quality is strongly associated with both depressive symptoms and decreased HRQoL in patients attending CR [161]. Furthermore, in patients recovering from a cardiac event (MI and/or revascularization) sleep disturbance was associated with poorer treatment adherence and predicted anxiety and depression 1 year later [162]. These findings suggest that sleep disturbance in cardiac patients may hamper rehabilitative efforts and demonstrate the importance of sleep evaluation in cardiac care. Consequently, in addition to identifying OSA, it has been strongly recommended that CR programmes should implement brief but comprehensive sleep assessments that discriminate patients who suffer from clinically significant insomnia that could put them at risk for a future major depressive episode [163]. The STOP-BANG [164] and the Insomnia Severity Index (ISI) [165] are recommended as initial CR screening measures for OSA and insomnia, respectively. CBT for insomnia (CBT-I) is an effective treatment with an efficacy that is better sustained than pharmacotherapy [166], but access is limited due to the lack of appropriately trained providers [167]. Although it is not yet an established component of cardiovascular care [168], there is emerging evidence that CBT-I improves biomarkers that may contribute to the CVD risk [169]. Looking forward, although sleep disturbance is clearly associated with increased risk cardiovascular disease, large randomised controlled trials are needed to determine whether ameliorating insomnia or optimising sleep more generally improves cardiovascular outcomes. Meeting this challenge may enable sleep to assume its place among "the top 10 modifiable risk factors for cardiovascular disease" [170].

Psychobiological and Behavioural Pathways Linking PSRFs and CVD

A detailed account of the various behavioural and pathophysiological mechanisms linking PSRFs and cardiovascular disease is beyond the scope of the current review. However, a number of common and interrelated pathways have been identified that may serve as plausible explanations for this relationship. The incidence and development of CVD can be brought about by direct physiological effects or indirectly via health behaviours. The psychobiological routes to cardiovascular endpoints can vary according to each PSRF but collectively include changes in the autonomic nervous system, the endocrine and inflammatory systems, insulin resistance, central adiposity, and endothelial and platelet dysfunction [171, 172••]. Behavioural pathways include unhealthy diet, lower levels of physical activity, excessive alcohol consumption [173, 174], reduced adherence to cardioprotective medications [84], and less engagement with secondary prevention programmes such as smoking cessation and cardiac rehabilitation [86, 87]. Financial barriers to accessing health care post-MI have also been predictive of poorer outcomes [175].

Rather than partial out their individual effects, future research in this area may benefit from investigating the synergistic relationships between PSRFs that may naturally cluster together. For example, a recent prospective study of 4487 adults with CHD provided evidence for a 'perfect storm' conceptual model whereby the confluence of depressive symptoms and concurrent high stress were more predictive of cardiac endpoints at 2.5 years than either PSRF alone [176].

Conclusion

Substantial research has demonstrated not only the critical importance of PSRFs to quality of life but also the aetiology and prognosis of CVD. The complex role of PSRFs is highlighted by the fact that they are thought to act on CVD outcomes via indirect and direct mechanisms. Another complicating factor is the interrelatedness of some of the PSRFs highlighted in this review. For example, depression is highly co-morbid with personality, anger, anxiety, poorer HRQoL, sleep disturbance, and even aspects of disease severity, such as left ventricular dysfunction. Large studies are needed to elucidate these relationships and to determine if these are true risk factors or better seen as risk markers for CVD outcomes. Such studies should also provide a renewed focus on sleep, which could provide a promising avenue for comprehensive behavioural management of related PSRFs and possibly to impact harder endpoints. What is clear from the literature is that the assessment and treatment of such PSRFs do enhance quality of life, and there is a clear ethical obligation to provide such comprehensive, effective psychosocial care.

Compliance with Ethical Guidelines

Conflict of Interest   Jonathan Gallagher and Giulia Parenti declare that they have no conflict of interest.
  Frank Doyle reports personal fees from Novartis.

Human and Animal Rights and Informed Consent   This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as:
• Of importance
•• Of major importance

1. Dimsdale JE. Psychological stress and cardiovascular disease. J Am Coll Cardiol. 2008;51(13):1237–46. doi:10.1016/j.jacc.2007.12.024.

2.•• Pogosova N, Saner H, Pedersen SS, Cupples ME, McGee H, Hofer S, et al. Psychosocial aspects in cardiac rehabilitation: from theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol. 2014. doi:10.1177/2047487314543075. **Excellent overview of PSRFs including recommendations for measurement**.

3. Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA, et al. Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case–control study. Lancet. 2004;364(9438):953–62. doi:10.1016/S0140-6736(04)17019-0.

4. Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A. Socioeconomic status and cardiovascular disease: risks and implications for care. Nat Rev Cardiol. 2009;6(11):712–22. doi:10.1038/nrcardio.2009.163.

5. Woodward M, Peters SA, Batty GD, Ueshima H, Woo J, Giles GG, et al. Socioeconomic status in relation to cardiovascular disease and cause-specific mortality: a comparison of Asian and Australasian populations in a pooled analysis. BMJ Open. 2015;5(3):e006408. doi:10.1136/bmjopen-2014-006408.

6. Galobardes B, Smith GD, Lynch JW. Systematic review of the influence of childhood socioeconomic circumstances on risk for cardiovascular disease in adulthood. Ann Epidemiol. 2006;16(2):91–104. doi:10.1016/j.annepidem.2005.06.053.

7. Gerber Y, Goldbourt U, Drory Y. Israel study group on first acute myocardial I. Interaction between income and education in predicting long-term survival after acute myocardial infarction. Eur J Cardiovasc Prev Rehabil. 2008;15(5):526–32. doi:10.1097/HJR.0b013e328304feac.

8. Gupta R, Islam S, Mony P, Kutty VR, Mohan V, Kumar R, Thakur J, Shankar VK, Mohan D, Vijayakumar K, Rahman O, Yusuf R, Iqbal R, Shahid M, Mohan I, Rangarajan S, Teo KK, Yusuf S. Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: the PURE study. Eur J Prev Cardiol. 2014.

9. Bruthans J, Mayer O Jr, De Bacquer D, De Smedt D, Reiner Z, Kotseva K, Cífková R, EUROASPIRE IV investigators. Educational level and risk profile and risk control in patients with coronary heart disease. Eur J Prev Cardiol. 2015.

10. Jankowski P, Pajak A, Lysek R, Lukaszewska A, Wolfshaut-Wolak R, Bogacki P, et al. Cardiac rehabilitation in real life. Medicine (Baltimore). 2015;94(32):e1257. doi:10.1097/MD.0000000000001257.

11.•• Neubeck L, Freedman SB, Clark AM, Briffa T, Bauman A, Redfern J. Participating in cardiac rehabilitation: a systematic review and meta-synthesis of qualitative data. Eur J Prev Cardiol. 2012;19(3):494–503. **An important insight into patient reported barriers**.

12. Gaalema DE, Higgins ST, Shepard DS, Suaya JA, Savage PD, Ades PA. State-by-state variations in cardiac rehabilitation participation are associated with educational attainment, income, and program availability. J Cardiopulm Rehabil Prev. 2014;34(4):248–54. doi:10.1097/HCR.0000000000000059.

13. Alter DA, Franklin B, Ko DT, Austin PC, Lee DS, Oh PI, et al. Socioeconomic status, functional recovery, and long-term mortality among patients surviving acute myocardial infarction. PLoS One. 2014;8(6):e65130. doi:10.1371/journal.pone.0065130.

14. Dankner R, Drory Y, Geulayov G, Ziv A, Novikov I, Zlotnick AY, et al. A controlled intervention to increase participation in cardiac rehabilitation. Eur J Prev Cardiol. 2015;22(9):1121–8. doi:10.1177/2047487314548815.

15. Karmali KN, Davies P, Taylor F, Beswick A, Martin N, Ebrahim S. Promoting patient uptake and adherence in cardiac

rehabilitation. Cochrane Database Syst Rev. 2014;6:CD007131. doi:10.1002/14651858.CD007131.pub3.

16. Ades PA, Gaalema DE. Coronary heart disease as a case study in prevention: potential role of incentives. Prev Med. 2012;55(Suppl):S75–9. doi:10.1016/j.ypmed.2011.12.025.

17. Gaalema DE, Cutler AY, Higgins ST, Ades PA. Smoking and cardiac rehabilitation participation: associations with referral, attendance and adherence. Prev Med. 2015. doi:10.1016/j.ypmed.2015.04.009.

18. Bucholz EM, Rathore SS, Gosch K, Schoenfeld A, Jones PG, Buchanan DM, et al. Effect of living alone on patient outcomes after hospitalization for acute myocardial infarction. Am J Cardiol. 2011;108(7):943–8. doi:10.1016/j.amjcard.2011.05.023.

19. Barth J, Schneider S, von Kanel R. Lack of social support in the etiology and the prognosis of coronary heart disease: a systematic review and meta-analysis. Psychosom Med. 2010;72(3):229–38. doi:10.1097/PSY.0b013e3181d01611.

20. Frasure-Smith N, Lesperance F, Gravel G, Masson A, Juneau M, Talajic M, et al. Social support, depression, and mortality during the first year after myocardial infarction. Circulation. 2000;101(16):1919–24.

21. Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. 2003;289(23):3106–16. doi:10.1001/jama.289.23.3106.

22. Lurie I, Myers V, Goldbourt U, Gerber Y. Perceived social support following myocardial infarction and long-term development of frailty. Eur J Prev Cardiol. 2014.

23. Pinto BM, Dunsiger SI. Mediators of exercise maintenance after cardiac rehabilitation. J Cardiopulm Rehabil Prev. 2015;35(1):13–20. doi:10.1097/HCR.0000000000000065.

24. Burg MM, Barefoot J, Berkman L, Catellier DJ, Czajkowski S, Saab P, et al. Low perceived social support and post-myocardial infarction prognosis in the enhancing recovery in coronary heart disease clinical trial: the effects of treatment. Psychosom Med. 2005;67(6):879–88. doi:10.1097/01.psy.0000188480.61949.8c.

25. Friedman M, Rosenman RH. Association of specific overt behavior pattern with blood and cardiovascular findings; blood cholesterol level, blood clotting time, incidence of arcus senilis, and clinical coronary artery disease. J Am Med Assoc. 1959;169(12):1286–96.

26. Myrtek M. Meta-analyses of prospective studies on coronary heart disease, type A personality, and hostility. Int J Cardiol. 2001;79(2–3):245–51.

27.•• Whalley B, Thompson DR, Taylor RS. Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Int J Behav Med. 2014;21(1):109–21. doi:10.1007/s12529-012-9282-x. **A clear overview of important RCTs in the area**.

28. Gulliksson M, Burell G, Vessby B, Lundin L, Toss H, Svardsudd K. Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med. 2011;171(2):134–40. doi:10.1001/archinternmed.2010.510.

29. Orth-Gomer K, Schneiderman N, Wang HX, Walldin C, Blom M, Jernberg T. Stress reduction prolongs life in women with coronary disease: the Stockholm Women's Intervention Trial for Coronary Heart Disease (SWITCHD). Circ Cardiovasc Qual Outcomes. 2009;2(1):25–32. doi:10.1161/CIRCOUTCOMES.108.812859.

30. Younge JO, Gotink RA, Baena CP, Roos-Hesselink JW, Hunink MM. Mind-body practices for patients with cardiac disease: a systematic review and meta-analysis. Eur J Prev Cardiol. 2014.

31. Smith TW. Concepts and methods in the study of anger, hostility and health. In: Siegman AW, Smith TW, editors. Anger, hostility and the heart. Hillsdale: Erlbaum; 1994. p. 23–42.

32. Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. J Am Coll Cardiol. 2009;53(11):936–46. doi:10.1016/j.jacc.2008.11.044.

33. Skala JA, Freedland K, Carney R. Advances in psychotherapy—evidence based practice: heart disease. Cambridge: Hogrefe & Huber; 2005.

34. Mostofsky E, Maclure M, Tofler GH, Muller JE, Mittleman MA. Relation of outbursts of anger and risk of acute myocardial infarction. Am J Cardiol. 2013;112(3):343–8. doi:10.1016/j.amjcard.2013.03.035.

35. Russell DC, Smith TL, Krahn DD, Graskamp P, Singh D, Kolden GG, et al. Effects of cognitive behavioral stress management on negative mood and cardiac autonomic activity in ICD recipients. Pacing Clin Electrophysiol. 2015;38(8):951–65. doi:10.1111/pace.12668.

36. Lavie CJ, Milani RV. Prevalence of anxiety in coronary patients with improvement following cardiac rehabilitation and exercise training. Am J Cardiol. 2004;93(3):336–9. doi:10.1016/J.Amjcard.2003.10.015.

37. Milani RV, Lavie CJ. Reducing psychosocial stress: a novel mechanism of improving survival from exercise training. Am J Med. 2009;122(10):931–8. doi:10.1016/j.amjmed.2009.03.028.

38. Arnold SV, Spertus JA, Nallamothu BK. The hostile heart: anger as a trigger for acute cardiovascular events. Eur Heart J. 2014;35(21):1359–60. doi:10.1093/eurheartj/ehu097.

39. Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med. 2005;67(1):89–97. doi:10.1097/01.psy.0000149256.81953.49.

40. Doyle F, McGee HM, Delaney M, Motterlini N, Conroy RM. Depressive vulnerabilities predict depression status and trajectories of depression over one year in persons with acute coronary syndrome. Gen Hosp Psychiatry. 2011;33(3):224–31. doi:10.1016/j.genhosppsych.2011.03.008.

41. Williams L, O'Connor RC, Howard S, Hughes BM, Johnston DW, Hay JL, et al. Type-D personality mechanisms of effect: the role of health-related behavior and social support. J Psychosom Res. 2008;64(1):63–9. doi:10.1016/j.jpsychores.2007.06.008.

42. Williams L, O'Connor RC, Grubb N, O'Carroll R. Type D personality predicts poor medication adherence in myocardial infarction patients. Psychol Health. 2011;26(6):703–12. doi:10.1080/08870446.2010.488265.

43. Williams L, Abbott C, Kerr R. Health behaviour mediates the relationship between Type D personality and subjective health in the general population. J Health Psychol. 2015. doi:10.1177/1359105315571977.

44. Sogaro E, Schinina F, Burgisser C, Orso F, Pallante R, Aloi T, et al. Type D personality impairs quality of life, coping and short-term psychological outcome in patients attending an outpatient intensive program of cardiac rehabilitation. Monaldi Arch Chest Dis. 2010;74(4):181–91.

45. Denollet J, Schiffer AA, Spek V. A general propensity to psychological distress affects cardiovascular outcomes: evidence from research on the type D (distressed) personality profile. Circ Cardiovasc Qual Outcomes. 2010;3(5):546–57. doi:10.1161/CIRCOUTCOMES.109.934406.

46. Grande G, Romppel M, Barth J. Association between type D personality and prognosis in patients with cardiovascular diseases: a systematic review and meta-analysis. Ann Behav Med Publ Soc Behav Med. 2012;43(3):299–310. doi:10.1007/s12160-011-9339-0.

47. Pelle AJ, Pedersen SS, Schiffer AA, Szabo B, Widdershoven JW, Denollet J. Psychological distress and mortality in systolic heart

failure. Circ Heart Fail. 2010;3(2):261–7. doi:10.1161/CIRCHEARTFAILURE.109.871483.

48. Coyne JC, Jaarsma T, Luttik ML, van Sonderen E, van Veldhuisen DJ, Sanderman R. Lack of prognostic value of type D personality for mortality in a large sample of heart failure patients. Psychosom Med. 2011;73(7):557–62. doi:10.1097/PSY.0b013e318227ac75.

49. Grande G, Romppel M, Vesper JM, Schubmann R, Glaesmer H, Herrmann-Lingen C. Type D personality and all-cause mortality in cardiac patients—data from a German cohort study. Psychosom Med. 2011;73(7):548–56. doi:10.1097/PSY.0b013e318227a9bc.

50. Dulfer K, Hazemeijer BA, Van Dijk MR, Van Geuns RJ, Daemen J, Van Domburg RT, et al. Prognostic value of type D personality for 10-year mortality and subjective health status in patients treated with percutaneous coronary intervention. J Psychosom Res. 2015. doi:10.1016/j.jpsychores.2015.05.014.

51. de Voogd JN, Sanderman R, Coyne JC. A meta-analysis of spurious associations between type D personality and cardiovascular disease endpoints. Ann Behav Med Publ Soc Behav Med. 2012;44(1):136–7. doi:10.1007/s12160-012-9356-7.

52. Ferguson E, Williams L, O'Connor RC, Howard S, Hughes BM, Johnston DW, et al. A taxometric analysis of type-D personality. Psychosom Med. 2009;71(9):981–6. doi:10.1097/PSY.0b013e3181bd888b.

53. Pelle AJ, Erdman RA, van Domburg RT, Spiering M, Kazemier M, Pedersen SS. Type D patients report poorer health status prior to and after cardiac rehabilitation compared to non-type D patients. Ann Behav Med. 2008;36(2):167–75.

54. Pelle AJ, van den Broek KC, Denollet J. Interventions in the context of the distressed (type D) personality. In: Dornelas E, editor. Stress proof the heart: behavioural interventions for cardiac patients. New York: Springer; 2012.

55. Karasek R, Theorell T. Healthy work: stress, productivity, and the reconstruction of working life. Basic books; 1992.

56. Kivimaki M, Nyberg ST, Batty GD, Fransson EI, Heikkila K, Alfredsson L, et al. Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data. Lancet. 2012;380(9852):1491–7. doi:10.1016/S0140-6736(12)60994-5.

57. Siegrist J. Adverse health effects of high-effort/low-reward conditions. J Occup Health Psychol. 1996;1(1):27.

58. Eller NH, Netterstrom B, Gyntelberg F, Kristensen TS, Nielsen F, Steptoe A, et al. Work-related psychosocial factors and the development of ischemic heart disease: a systematic review. Cardiol Rev. 2009;17(2):83–97. doi:10.1097/CRD.0b013e318198c8e9.

59. Yonezawa R, Masuda T, Matsunaga A, Takahashi Y, Saitoh M, Ishii A, et al. Effects of phase II cardiac rehabilitation on job stress and health-related quality of life after return to work in middle-aged patients with acute myocardial infarction. Int Heart J. 2009;50(3):279–90.

60. AACVPR. Guidelines for cardiac rehabilitation and secondary prevention programs (5th edition). Human Kinetics Press, 2013.

61. Cho EN, von Kanel R. Job stress and overcommitment in cardiac patients. In: Dornelas E, editor. Stress proof the heart: behavioural interventions for cardiac patients. New York: Springer; 2012.

62. Nawrot TS, Perez L, Kunzli N, Munters E, Nemery B. Public health importance of triggers of myocardial infarction: a comparative risk assessment. Lancet. 2011;377(9767):732–40. doi:10.1016/S0140-6736(10)62296-9.

63. Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Gerstenblith G, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005;352(6):539–48. doi:10.1056/NEJMoa043046.

64. Steinberg JS, Arshad A, Kowalski M, Kukar A, Surna V, Vloka M, et al. Increased incidence of life-threatening ventricular arrhythmias in implantable defibrillator patients after the world trade center attack. J Am Coll Cardiol. 2004;44(6):1261–4. doi:10.1016/J.Jacc.2004.06.032.

65.• Mostofsky E, Penner EA, Mittleman MA. Outbursts of anger as a trigger of acute cardiovascular events: a systematic review and meta-analysis. Eur Heart J. 2014;35(21):1404–10. doi:10.1093/eurheartj/ehu033. **Important meta-analysis quantifying the effects of anger on acute CVD onset**.

66. Carroll D, Ebrahim S, Tilling K, MacLeod J, Smith GD. Admissions for myocardial infarction and World Cup football: database survey. Br Med J. 2002;325(7378):1439–42. doi:10.1136/Bmj.325.7378.1439.

67. Li J, Hansen D, Mortensen PB, Olsen J. Myocardial infarction in parents who lost a child: a nationwide prospective cohort study in Denmark. Circulation. 2002;106(13):1634–9.

68. Perkins-Porras L, Joekes K, Bhalla N, Sutherland C, Pollard M. Reporting of posttraumatic stress disorder and cardiac misconceptions following cardiac rehabilitation. J Cardiopulm Rehabil Prev. 2015;35(4):238–45. doi:10.1097/HCR.0000000000000100.

69. Campbell TS, Stevenson A, Arena R, Hauer T, Bacon SL, Rouleau CR, et al. An investigation of the benefits of stress management within a cardiac rehabilitation population. J Cardiopulm Rehabil Prev. 2012;32(5):296–304.

70. Whalley B, Rees K, Davies P, Bennett P, Ebrahim S, Liu ZL, et al. Psychological interventions for coronary heart disease. Cochrane Database Syst Rev. 2011;8:Cd002902. doi:10.1002/14651858.Cd002902.

71. Cramer H, Lauche R, Haller H, Dobos G, Michalsen A. A systematic review of yoga for heart disease. Eur J Prev Cardiol. 2015;22(3):284–95. doi:10.1177/2047487314523132.

72. Linden W, Phillips MJ, Leclerc J. Psychological treatment of cardiac patients: a meta-analysis. Eur Heart J. 2007;28(24):2972–84.

73. Allan R. Observations of a clinical cardiac psychologist. In: Allan R, Fisher J, editors. Heart and mind: the practice of cardiac psychology. Washington: American Psychological Association; 2012. p. 475–86.

74.• Doyle F, McGee H, Conroy RM, Conradi HJ, Meijer A, Steeds RP, et al. Systematic review and individual patient data meta-analysis of sex differences in depression and prognosis in persons with myocardial infarction: a MINDMAPS study. Psychosom Med. 2015;77(4):419–28. doi:10.1097/PSY.0000000000000174. **This meta-analysis highlights the complexity of depression post-MI, with symptoms differentially associated with left ventricular function by sex**.

75.•• Meijer A, Conradi HJ, Bos EH, Anselmino M, Carney RM, Denollet J, et al. Adjusted prognostic association of depression following myocardial infarction with mortality and cardiovascular events: individual patient data meta-analysis. Br J Psychiatry. 2013;203(2):90–102. doi:10.1192/bjp.bp.112.111195. **Up to date meta-analysis of association between depression and post-MI morbidity and mortality**.

76. Thombs BD, Bass EB, Ford DE, Stewart KJ, Tsilidis KK, Patel U, et al. Prevalence of depression in survivors of acute myocardial infarction—review of the evidence. J Gen Intern Med. 2006;21(1):30–8. doi:10.1111/J.1525-1497.2005.00269x.

77. Kaptein KI, de Jonge P, van den Brink RH, Korf J. Course of depressive symptoms after myocardial infarction and cardiac prognosis: a latent class analysis. Psychosom Med. 2006;68(5):662–8. doi:10.1097/01.psy.0000233237.79085.57.

78. Magyar-Russell G, Thombs BD, Cai JX, Baveja T, Kuhl EA, Singh PP, et al. The prevalence of anxiety and depression in adults with implantable cardioverter defibrillators: a systematic review. J Psychosom Res. 2011;71(4):223–31. doi:10.1016/j.jpsychores.2011.02.014.

79. Whang W, Albert CM, Sears Jr SF, Lampert R, Conti JB, Wang PJ, et al. Depression as a predictor for appropriate shocks among patients with implantable cardioverter-defibrillators: results from

the Triggers of Ventricular Arrhythmias (TOVA) study. J Am Coll Cardiol. 2005;45(7):1090–5. doi:10.1016/j.jacc.2004.12.053.

80. Tzeis S, Kolb C, Baumert J, Reents T, Zrenner B, Deisenhofer I, et al. Effect of depression on mortality in implantable cardioverter defibrillator recipients—findings from the prospective LICAD study. Pacing Clin Electrophysiol PACE. 2011;34(8):991–7. doi:10.1111/j.1540-8159.2011.03081.x.

81. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure—a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006;48(8):1527–37. doi:10.1016/J.Jacc.2006.06.055.

82. Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J. 2006;27(23):2763–74. doi:10.1093/Eurheartj/Ehl338.

83.• Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. 2014;129(12):1350–69. doi:10.1161/cir.0000000000000019. **Review and recommendations of AHA working group on depression**.

84. Rieckmann N, Gerin W, Kronish IM, Burg MM, Chaplin WF, Kong G, et al. Course of depressive symptoms and medication adherence after acute coronary syndromes: an electronic medication monitoring study. J Am Coll Cardiol. 2006;48(11):2218–22. doi:10.1016/j.jacc.2006.07.063.

85. Rieckmann N, Kronish IM, Haas D, Gerin W, Chaplin WF, Burg MM, et al. Persistent depressive symptoms lower aspirin adherence after acute coronary syndromes. Am Heart J. 2006;152(5):922–7. doi:10.1016/j.ahj.2006.05.014.

86. Doyle F, Rohde D, Rutkowska A, Morgan K, Cousins G, McGee H. Systematic review and meta-analysis of the impact of depression on subsequent smoking cessation in patients with coronary heart disease: 1990 to 2013. Psychosom Med. 2014;76(1):44–57. doi:10.1097/psy.0000000000000020.

87. Glazer KM, Emery CF, Frid DJ, Banyasz RE. Psychological predictors of adherence and outcomes among patients in cardiac rehabilitation. J Cardiopulm Rehabil Prev. 2002;22(1):40–6.

88. McGrady A, McGinnis R, Badenhop D, Bentle M, Rajput M. Effects of depression and anxiety on adherence to cardiac rehabilitation. J Cardiopulm Rehabil Prev. 2009;29(6):358–64. doi:10.1097/HCR.0b013e3181be7a8f.

89. Pedersen SS, Denollet J, Daemen J, van de Sande M, de Jaegere PT, Serruys PW, et al. Fatigue, depressive symptoms, and hopelessness as predictors of adverse clinical events following percutaneous coronary intervention with paclitaxel-eluting stents. J Psychosom Res. 2007;62(4):455–61.

90. Leroy M, Loas G, Perez-Diaz F. Anhedonia as predictor of clinical events after acute coronary syndromes: a 3-year prospective study. Compr Psychiatry. 2010;51(1):8–14.

91.• de Miranda Azevedo R, Roest AM, Hoen PW, de Jonge P. Cognitive/affective and somatic/affective symptoms of depression in patients with heart disease and their association with cardiovascular prognosis: a meta-analysis. Psychol Med. 2014;44(13):2689–703. doi:10.1017/S0033291714000063. **Meta-analysis highlighting the importance of somatic depressive symptoms**.

92. Meijer A, Zuidersma M, de Jonge P. Depression as a non-causal variable risk marker in coronary heart disease. BMC Med. 2013;11:130. doi:10.1186/1741-7015-11-130.

93. Lespérance F, Frasure-Smith N, Koszycki D, Laliberté MA, van Zyl LT, Baker B, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. 2007;297(4):367–79.

94.•• Davidson KW, Rieckmann N, Clemow L, Schwartz JE, Shimbo D, Medina V, et al. Enhanced depression care for patients with acute coronary syndrome and persistent depressive symptoms coronary psychosocial evaluation studies randomized controlled trial. Arch Intern Med. 2010;170(7):600–8. **This high-quality RCT demonstrates how best to manage depressive symptoms in this population**.

95. Colquhoun DM, Bunker SJ, Clarke DM, Glozier N, Hare DL, Hickie IB, et al. Screening, referral and treatment for depression in patients with coronary heart disease. Med J Aust. 2013;198(9):483–4. doi:10.5694/Mja13.10153.

96.•• Davidson KW, Bigger JT, Burg MM, Carney RM, Chaplin WF, Czajkowski S, et al. Centralized, stepped, patient preference-based treatment for patients with post-acute coronary syndrome depression: CODIACS vanguard randomized controlled trial. JAMA Intern Med. 2013;173(11):997–1004. doi:10.1001/jamainternmed.2013.915. **This high-quality RCT demonstrates how best to manage depressive symptoms in this population**.

97.•• Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Smith PJ, Hoffman BM, et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease. J Am Coll Cardiol. 2012;60(12):1053–63. doi:10.1016/J.Jacc.2012.04.040. **This high-quality RCT demonstrates how best to manage depressive symptoms in this population**.

98.•• Blumenthal JA, Babyak MA, O'Connor C, Keteyian S, Landzberg J, Howlett J, et al. Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. JAMA. 2012;308(5):465–74. **This high-quality RCT demonstrates how best to manage depressive symptoms in this population**.

99. Ye S, Shaffer JA, Rieckmann N, Schwartz JE, Kronish IM, Ladapo JA, et al. Long-term outcomes of enhanced depression treatment in patients with acute coronary syndromes. Am J Med. 2014;127(10):1012–6. doi:10.1016/j.amjmed.2014.05.004.

100. O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. 2010;56(9):692–9. doi:10.1016/j.jacc.2010.03.068.

101. Ladwig KH, Lederbogen F, Albus C, Angermann C, Borggrefe M, Fischer D, et al. Position paper on the importance of psychosocial factors in cardiology: update 2013. Ger Med Sci GMS e-journal. 2014;12:Doc09. doi:10.3205/000194.

102. Cahill MC, Bilanovic A, Kelly S, Bacon S, Grace SL. Screening for depression in cardiac rehabilitation: a review. J Cardiopulm Rehabil Prev. 2015;35(4):225–30. doi:10.1097/HCR.0000000000000101.

103. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of the prime-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire. JAMA. 1999;282(18):1737–44.

104. Shapiro P. Management of depression after myocardial infarction. Curr Cardiol Rep. 2015;17(10):634. doi:10.1007/s11886-015-06.

105. Tully PJ, Cosh SM. Generalized anxiety disorder prevalence and comorbidity with depression in coronary heart disease: a meta-analysis. J Health Psychol. 2013;18(12):1601–16. doi:10.1177/1359105312467390.

106. Lane D, Carroll D, Ring C, Beevers DG, Lip GYH. The prevalence and persistence of depression and anxiety following myocardial infarction. Brit J Health Psych. 2002;7:11–21. doi:10.1348/135910702169321.

107. Easton K, Coventry P, Lovell K, Carter LA, Deaton C. Prevalence and measurement of anxiety in samples of patients with heart

failure: meta-analysis. J Cardiovasc Nurs. 2015. doi:10.1097/jcn.0000000000000265.

108. Morken IM, Isaksen K, Karlsen B, Norekval TM, Bru E, Larsen AI. Shock anxiety among implantable cardioverter defibrillator recipients with recent tachyarrhythmia. Pacing Clin Electrophysiol PACE. 2012;35(11):1369–76. doi:10.1111/j.1540-8159.2012.03505.x.

109. Edmondson D, Richardson S, Falzon L, Davidson KW, Mills MA, Neria Y. Posttraumatic stress disorder prevalence and risk of recurrence in acute coronary syndrome patients: a meta-analytic review. PLoS One. 2012;7(6):e38915. doi:10.1371/journal.pone.0038915.

110. Edmondson D, Kronish IM, Shaffer JA, Falzon L, Burg MM. Posttraumatic stress disorder and risk for coronary heart disease: a meta-analytic review. Am Heart J. 2013;166(5):806–14. doi:10.1016/j.ahj.2013.07.031.

111. Ladwig KH, Baumert J, Marten-Mittag B, Kolb C, Zrenner B, Schmitt C. Posttraumatic stress symptoms and predicted mortality in patients with implantable cardioverter-defibrillators: results from the prospective living with an implanted cardioverter-defibrillator study. Arch Gen Psychiatry. 2008;65(11):1324–30. doi:10.1001/archpsyc.65.11.1324.

112. Tully PJ, Baune BT. Comorbid anxiety disorders alter the association between cardiovascular diseases and depression: the German national health interview and examination survey. Soc Psychiatry Psychiatr Epidemiol. 2014;49(5):683–91. doi:10.1007/s00127-013-0784-x.

113. Martens EJ, de Jonge P, Na B, Cohen BE, Lett H, Whooley MA. Scared to death? Generalized anxiety disorder and cardiovascular events in patients with stable coronary heart disease: the heart and soul study. Arch Gen Psychiatry. 2010;67(7):750–8. doi:10.1001/archgenpsychiatry.2010.74.

114. Seldenrijk A, Vogelzangs N, Batelaan NM, Wieman I, van Schaik DJ, Penninx BJ. Depression, anxiety and 6-year risk of cardiovascular disease. J Psychosom Res. 2015;78(2):123–9. doi:10.1016/j.jpsychores.2014.10.007.

115. Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and risk of incident coronary heart disease a meta-analysis. J Am Coll Cardiol. 2010;56(1):38–46. doi:10.1016/J.Jacc.2010.03.034.

116. Roest AM, Martens EJ, Denollet J, de Jonge P. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: a meta-analysis. Psychosom Med. 2010;72(6):563–9. doi:10.1097/PSY.0b013e3181dbff97.

117. van Dijk MR, Utens EM, Dulfer K, Al-Qezweny MN, van Geuns RJ, Daemen J, van Domburg RT. Depression and anxiety symptoms as predictors of mortality in PCI patients at 10 years of follow-up. Eur J Prev Cardiol. 2015.

118. Bauer LK, Caro MA, Beach SR, Mastromauro CA, Lenihan E, Januzzi JL, et al. Effects of depression and anxiety improvement on adherence to medication and health behaviors in recently hospitalized cardiac patients. Am J Cardiol. 2012;109(9):1266–71. doi:10.1016/j.amjcard.2011.12.017.

119. Meyer T, Hussein S, Lange HW, Herrmann-Lingen C. Anxiety is associated with a reduction in both mortality and major adverse cardiovascular events five years after coronary stenting. Eur J Prev Cardiol. 2015;22(1):75–82. doi:10.1177/2047487313505244.

120. Huffman JC, Mastromauro CA, Beach SR, Celano CM, DuBois CM, Healy BC, et al. Collaborative care for depression and anxiety disorders in patients with recent cardiac events: the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized clinical trial. JAMA Intern Med. 2014;174(6):927–35. doi:10.1001/jamainternmed.2014.739.

121. Celano CM, Suarez L, Matromauro C, Januzzi JL, Hjuffan JC. Feasibility and utility of screening for depression and anxiety disorders in patients with cardiovascular disease. Circ Cardiovasc Qual Outcomes. 2013;6:498–504.

122. Hoekstra T, Jaarsma T, van Veldhuisen DJ, Hillege HL, Sanderman R, Lesman-Leegte I. Quality of life and survival in patients with heart failure. Eur J Heart Fail. 2013;15(1):94–102. doi:10.1093/eurjhf/hfs148.

123. Mastenbroek MH, Versteeg H, Zijlstra WP, Meine M, Spertus JA, Pedersen SS. Disease-specific health status as a predictor of mortality in patients with heart failure: a systematic literature review and meta-analysis of prospective cohort studies. Eur J Heart Fail. 2014;16(4):384–93. doi:10.1002/Ejhf.55.

124. Mommersteeg PMC, Denollet J, Spertus JA, Pedersen SS. Health status as a risk factor in cardiovascular disease: a systematic review of current evidence. Am Heart J. 2009;157(2):208–18. doi:10.1016/J.Ahj.2008.09.020.

125. Serber ER, Todaro JF, Tilkemeier PL, Niaura R. Prevalence and characteristics of multiple psychiatric disorders in cardiac rehabilitation patients. J Cardiopulm Rehabil Prev. 2009;29(3):161–8.

126. Cupples ME, Tully MA, Dempster M, Corrigan M, McCall DO, Downey B. Cardiac rehabilitation uptake following myocardial infarction: cross-sectional study in primary care. Br J Gen Pract. 2010;60(575):431–5. doi:10.3399/Bjgp10x502155.

127. Anderson L, Taylor RS. Cardiac rehabilitation for people with heart disease: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev. 2014;12:Cd011273.

128. De Smedt D, Clays E, Annemans L, Boudrez H, De Sutter J, Doyle F, et al. The association between self-reported lifestyle changes and health-related quality of life in coronary patients: the EUROASPIRE III survey. Eur J Prev Cardiol. 2014;21(7):796–805. doi:10.1177/2047487312473846.

129. Janssen V, De Gucht V, van Exel H, Maes S. Changes in illness perceptions and quality of life during participation in cardiac rehabilitation. Int J Behav Med. 2013;20(4):582–9. doi:10.1007/s12529-012-9260-3.

130. Oldridge N, Hofer S, McGee H, Conroy R, Doyle F, Saner H. The HeartQoL: part I. Development of a new core health-related quality of life questionnaire for patients with ischemic heart disease. Eur J Prev Cardiol. 2014;21(1):90–7. doi:10.1177/2047487312450544.

131. Oldridge N, Hofer S, McGee H, Conroy R, Doyle F, Saner H, et al. The HeartQoL: part II. Validation of a new core health-related quality of life questionnaire for patients with ischemic heart disease. Eur J Prev Cardiol. 2014;21(1):98–106. doi:10.1177/2047487312450545.

132. Hofer S, Saleem A, Stone J, Thomas R, Tulloch H, Oldridge N. The MacNew heart disease health-related quality of life questionnaire in patients with angina and patients with ischemic heart failure. Value Health. 2012;15(1):143–50. doi:10.1016/j.jval.2011.07.003.

133. Hansen TB, Thygesen LC, Zwisler AD, Helmark L, Hoogwegt M, Versteeg H, et al. Self-reported health-related quality of life predicts 5-year mortality and hospital readmissions in patients with ischaemic heart disease. Eur J Prev Cardiol. 2015;22(7):882–9. doi:10.1177/2047487314535682.

134. Höfer S, Benzer W, Oldridge N. Change in health-related quality of life in patients with coronary artery disease predicts 4-year mortality. Int J Cardiol. 2014;174(1):7–12. doi:10.1016/j.ijcard.2014.03.144.

135. Laugsand LE, Strand LB, Platou C, Vatten LJ, Janszky I. Insomnia and the risk of incident heart failure: a population study. Eur Heart J. 2014;35(21):1382–93. doi:10.1093/eurheartj/eht019.

136. Laugsand LE, Vatten LJ, Platou C, Janszky I. Insomnia and the risk of acute myocardial infarction: a population study. Circulation. 2011;124(19):2073–81. doi:10.1161/circulationaha.111.025858.

137. Reitav J. Managing sleep problems among cardiac patients. In: Dornelas E, editor. Stress proof the heart: behavioural interventions for cardiac patients. New York: Springer; 2012.

138. Vyas MV, Garg AX, Iansavichus AV, Costella J, Donner A, Laugsand LE, et al. Shift work and vascular events: systematic review and meta-analysis. BMJ. 2012;345:e4800.

139. Cappuccio FP, Cooper D, D'Elia L, Strazzullo P, Miller MA. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J. 2011;32(12):1484–92. doi:10.1093/eurheartj/ehr007.

140. Rozanski A. Behavioral cardiology: current advances and future directions. J Am Coll Cardiol. 2014;64(1):100–10. doi:10.1016/j.jacc.2014.03.047.

141. Gangwisch JE. A review of evidence for the link between sleep duration and hypertension. Am J Hypertens. 2014;27(10):1235–42. doi:10.1093/ajh/hpu071.

142. Jackowska M, Steptoe A. Sleep and future cardiovascular risk: prospective analysis from the English longitudinal study of ageing. Sleep Med. 2015;16(6):768–74. doi:10.1016/j.sleep.2015.02.530.

143. Knutson KL. Sleep duration and cardiometabolic risk: a review of the epidemiologic evidence. Best Pract Res Clin Endocrinol Metab. 2010;24(5):731–43. doi:10.1016/j.beem.2010.07.001.

144. Hoevenaar-Blom MP, Spijkerman AM, Kromhout D, Verschuren WM. Sufficient sleep duration contributes to lower cardiovascular disease risk in addition to four traditional lifestyle factors: the MORGEN study. Eur J Prev Cardiol. 2014;21(11):1367–75. doi:10.1177/2047487313493057.

145. Shamsuzzaman AS, Gersh BJ, Somers VK. Obstructive sleep apnea: implications for cardiac and vascular disease. JAMA. 2003;290(14):1906–14. doi:10.1001/jama.290.14.1906.

146. Mooe T, Franklin KA, Holmstrom K, Rabben T, Wiklund U. Sleep-disordered breathing and coronary artery disease: long-term prognosis. Am J Respir Crit Care Med. 2001;164(10 Pt 1):1910–3. doi:10.1164/ajrccm.164.10.2101072.

147. Skobel E, Kamke W, Bonner G, Alt B, Purucker HC, Schwaab B, et al. Risk factors for, and prevalence of, sleep apnoea in cardiac rehabilitation facilities in Germany: the reha-sleep registry. Eur J Prev Cardiol. 2015;22(7):820–30. doi:10.1177/2047487314537916.

148. Hargens TA, Aron A, Newsome LJ, Austin JL, Shafer BM. Effects of obstructive sleep apnea on hemodynamic parameters in patients entering cardiac rehabilitation. J Cardiopulm Rehabil Prev. 2015;35(3):181–5. doi:10.1097/HCR.0000000000000102.

149. Cassar A, Morgenthaler TI, Lennon RJ, Rihal CS, Lerman A. Treatment of obstructive sleep apnea is associated with decreased cardiac death after percutaneous coronary intervention. J Am Coll Cardiol. 2007;50(14):1310–4. doi:10.1016/j.jacc.2007.06.028.

150. Milleron O, Pilliere R, Foucher A, de Roquefeuil F, Aegerter P, Jondeau G, et al. Benefits of obstructive sleep apnoea treatment in coronary artery disease: a long-term follow-up study. Eur Heart J. 2004;25(9):728–34. doi:10.1016/j.ehj.2004.02.008.

151. Somers VK, White DP, Amin R, Abraham WT, Costa F, Culebras A, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. 2008;118(10):1080–111. doi:10.1161/circulationaha.107.189375.

152. Ong JC, Crawford MR. Insomnia and obstructive sleep apnea. Sleep Med Clin. 2013;8(3):389–98. doi:10.1016/j.jsmc.2013.04.004.

153. Sofi F, Cesari F, Casini A, Macchi C, Abbate R, Gensini GF. Insomnia and risk of cardiovascular disease: a meta-analysis. Eur J Prev Cardiol. 2014;21(1):57–64. doi:10.1177/2047487312460020.

154. Grandner MA, Buxton OM, Jackson N, Sands-Lincoln M, Pandey A, Jean-Louis G. Extreme sleep durations and increased C-reactive protein: effects of sex and ethnoracial group. Sleep. 2013;36(5):769–779. doi:10.5665/sleep.2646.

155. Fernandez-Mendoza J, Vgontzas AN, Liao D, Shaffer ML, Vela-Bueno A, Basta M, et al. Insomnia with objective short sleep duration and incident hypertension: the Penn State Cohort. Hypertension. 2012;60(4):929–35. doi:10.1161/hypertensionaha.112.193268.

156. Vgontzas AN, Fernandez-Mendoza J, Liao D, Bixler EO. Insomnia with objective short sleep duration: the most biologically severe phenotype of the disorder. Sleep Med Rev. 2013;17(4):241–54. doi:10.1016/j.smrv.2012.09.005.

157. Li Y, Zhang X, Winkelman JW, Redline S, Hu FB, Stampfer M, et al. Association between insomnia symptoms and mortality: a prospective study of U.S. men. Circulation. 2014;129(7):737–46. doi:10.1161/circulationaha.113.004500.

158. Carney CE, Segal ZV, Edinger JD, Krystal AD. A comparison of rates of residual insomnia symptoms following pharmacotherapy or cognitive-behavioral therapy for major depressive disorder. J Clin Psychiatry. 2007;68(2):254–60.

159. Manber R, Edinger JD, Gress JL, San Pedro-Salcedo MG, Kuo TF, Kalista T. Cognitive behavioral therapy for insomnia enhances depression outcome in patients with comorbid major depressive disorder and insomnia. Sleep. 2008;31(4):489–95.

160. Coryell VT, Ziegelstein RC, Hirt K, Quain A, Marine JE, Smith MT. Clinical correlates of insomnia in patients with acute coronary syndrome. Int Heart J. 2013;54(5):258–65.

161. Banack HR, Holly CD, Lowensteyn I, Masse L, Marchand S, Grover SA, et al. The association between sleep disturbance, depressive symptoms, and health-related quality of life among cardiac rehabilitation participants. J Cardiopulm Rehabil Prev. 2014;34(3):188–94. doi:10.1097/HCR.0000000000000054.

162. Le Grande MR, Jackson AC, Murphy BM, Thomason N. Relationship between sleep disturbance, depression and anxiety in the 12 months following a cardiac event. Psychol Health Med. 2015;11:1–8.

163. Canadian Association for Cardiac Rehabilitation. Canadian guidelines for cardiac rehabilitation and cardiovascular disease prevention: translating knowledge into action. 2009.

164. Chung F, Yegneswaran B, Liao P, Chung SA, Vairavanathan S, Islam S, et al. STOP questionnaire: a tool to screen patients for obstructive sleep apnea. Anesthesiology. 2008;108(5):812–21.

165. Morin M. Insomnia: psychological assessment and management. New York: Guildford Press; 1993.

166. Morin CM, Vallières A, Guay B, Ivers H, Savard J, Mérette C, et al. Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: a randomized controlled trial. JAMA. 2009;301(19):2005–15.

167. Espie CA. "Stepped care": a health technology solution for delivering cognitive behavioral therapy as a first line insomnia treatment. Sleep. 2009;32(12):1549–58.

168. Conley S, Redeker NS. Cognitive behavioral therapy for insomnia in the context of cardiovascular conditions. Curr Sleep Med Rep. 2015;1:157–65. doi:10.1007/s40675-015-0019-7.

169. Irwin MR, Olmstead R, Carrillo C, Sadeghi N, Breen EC, Witarama T, et al. Cognitive behavioural therapy vs. Tai Chi for late life insomnia and inflammatory risk: a randomized controlled comparative efficacy trial. Sleep. 2014;37(9):1543–52. doi:10.5665/sleep.4008.

170. Redline S, Foody J. Sleep disturbances: time to join the top 10 potentially modifiable cardiovascular risk factors? Circulation. 2011;124(19):2049–51. doi:10.1161/CIRCULATIONAHA.111.062190.

171. Huffman JC, Celano CM, Beach SR, Motiwala SR, Januzzi JL. Depression and cardiac disease: epidemiology, mechanisms, and diagnosis. Cardiovasc Psychiatry Neurol. 2013;2013:695925. doi:10.1155/2013/695925.

172.•• Steptoe A, Kivimaki M. Stress and cardiovascular disease: an update on current knowledge. Annu Rev Public Health. 2013;34:337–54. doi:10.1146/annurev-publhealth-031912-114452. **An excellent overview of current knowledge of direct mechanisms linking stress to CVD**.

173. Hamer M, Molloy GJ, Stamatakis E. Psychological distress as a risk factor for cardiovascular events. J Am Coll Cardiol. 2008;52(25):2156–62. doi:10.1016/J.Jacc.2008.08.057.

174. Stringhini S, Sabia S, Shipley M, Brunner E, Nabi H, Kivimaki M, et al. Association of socioeconomic position with health behaviors and mortality. JAMA J Am Med Assoc. 2010;303(12):1159–66. doi:10.1001/Jama.2010.297.

175. Rahimi AR, Spertus JA, Reid KJ, Bernheim SM, Krumholz HM. Financial barriers to health care and outcomes after acute myocardial infarction. JAMA. 2007;297(10):1063–72. doi:10.1001/jama.297.10.1063.

176. Alcantara C, Muntner P, Edmondson D, Safford MM, Redmond N, Colantonio LD, et al. Perfect storm: concurrent stress and depressive symptoms increase risk of myocardial infarction or death. Circ Cardiovasc Qual Outcomes. 2015;8(2):146–54. doi:10.1161/circoutcomes.114.001180.